Stock FAGR FAGRON N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fagron N.V.

Equities

FAGR

BE0003874915

Pharmaceuticals

Market Closed - Euronext Bruxelles
Other stock markets
 11:38:33 2024-04-26 am EDT 		5-day change 1st Jan Change
17.76 EUR +0.68% Intraday chart for Fagron N.V. +0.91% +6.92%
Apr. 11 Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024
Apr. 11 Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,393 1,375 1,078 967.2 1,213 1,296 - -
Enterprise Value (EV) 1 1,678 1,647 1,343 1,241 1,447 1,525 1,474 1,453
P/E ratio 34.5 x 22.9 x 17.6 x 13.8 x 17.1 x 15.8 x 13.6 x 11.9 x
Yield 0.78% 0.95% 1.35% 1.88% 1.81% 1.64% 1.79% 1.96%
Capitalization / Revenue 2.61 x 2.47 x 1.88 x 1.41 x 1.59 x 1.54 x 1.45 x 1.36 x
EV / Revenue 3.14 x 2.96 x 2.34 x 1.82 x 1.9 x 1.81 x 1.65 x 1.52 x
EV / EBITDA 14.3 x 13.3 x 11.4 x 9.5 x 9.71 x 9.12 x 8.1 x 7.36 x
EV / FCF 30.5 x 22.1 x 23.3 x 13.6 x 16.8 x 15.9 x 12.1 x 11.2 x
FCF Yield 3.28% 4.53% 4.29% 7.33% 5.96% 6.3% 8.23% 8.91%
Price to Book 5.73 x 5.41 x 3.36 x 2.39 x 2.61 x 2.45 x 2.12 x 1.85 x
Nbr of stocks (in thousands) 72,075 72,374 72,857 72,889 73,030 72,987 - -
Reference price 2 19.33 19.00 14.80 13.27 16.61 17.76 17.76 17.76
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 2/15/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 534.7 556 573.8 683.9 763 841.2 895.4 955.1
EBITDA 1 117 123.9 118.3 130.7 149 167.2 182 197.6
EBIT 1 87.68 92.63 87.44 97.91 108.6 125.9 139.5 152.8
Operating Margin 16.4% 16.66% 15.24% 14.32% 14.24% 14.97% 15.58% 16%
Earnings before Tax (EBT) 1 69.89 73.72 - - - 107.4 123.4 136.6
Net income 1 41.06 60.04 61 69.61 70.55 82.27 96.23 109.9
Net margin 7.68% 10.8% 10.63% 10.18% 9.25% 9.78% 10.75% 11.51%
EPS 2 0.5600 0.8300 0.8400 0.9600 0.9700 1.123 1.310 1.493
Free Cash Flow 1 55 74.53 57.69 91 86.16 96 121.3 129.5
FCF margin 10.29% 13.41% 10.05% 13.31% 11.29% 11.41% 13.55% 13.56%
FCF Conversion (EBITDA) 47.01% 60.14% 48.75% 69.61% 57.84% 57.41% 66.65% 65.55%
FCF Conversion (Net income) 133.97% 124.14% 94.56% 130.72% 122.13% 116.69% 126.05% 117.83%
Dividend per Share 2 0.1500 0.1800 0.2000 0.2500 0.3000 0.2920 0.3180 0.3480
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 2/15/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2023 Q1
Net sales 1 276.6 181.4
EBITDA 56.01 -
EBIT 40.72 -
Operating Margin 14.72% -
Earnings before Tax (EBT) - -
Net income 26.95 -
Net margin 9.74% -
EPS - -
Dividend per Share - -
Announcement Date 8/5/21 5/15/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 285 272 265 274 234 228 177 157
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.435 x 2.192 x 2.239 x 2.097 x 1.569 x 1.366 x 0.9742 x 0.7958 x
Free Cash Flow 1 55 74.5 57.7 91 86.2 96 121 130
ROE (net income / shareholders' equity) 25.9% 25.4% 21.3% 19.2% 16.2% 16.8% 16.7% 16.5%
ROA (Net income/ Total Assets) 7.83% 8.1% - - - - - -
Assets 1 524.5 741.5 - - - - - -
Book Value Per Share 2 3.370 3.510 4.410 5.550 6.350 7.240 8.360 9.610
Cash Flow per Share 2 1.070 1.290 1.080 1.500 1.710 1.240 1.560 1.690
Capex 1 22.2 18.4 20.7 18.5 38.5 40.5 32.3 34.4
Capex / Sales 4.15% 3.31% 3.61% 2.71% 5.04% 4.81% 3.6% 3.6%
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 2/15/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Fagron N.V.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.76 EUR
Average target price
21.7 EUR
Spread / Average Target
+22.18%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
FAGRON N.V. Stock Fagron N.V.
+6.92% 1.38B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. FAGR Stock
  4. Financials Fagron N.V.